A cost-effectiveness analysis evaluating endoscopic surveillance for gastric cancer for populations with low to intermediate risk

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Zhou, Hui Jun ^a   Dan, Yock Young ^b   Naidoo, Nasheen ^a   Li, Shu Chuen ^c   Yeoh, Khay Guan ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b Dept Medicine Endocrinol Diabet   (Singapore)

^c UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; AGED; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; ENDOSCOPY; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMAN; MALE; MIDDLE AGED; PROBABILITY; RISK; SEX RATIO; STOMACH TUMOR;

AGE DISTRIBUTION; AGED; COST-BENEFIT ANALYSIS; ENDOSCOPY; EPIDEMIOLOGICAL MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PROBABILITY; RISK; SEX DISTRIBUTION; STOMACH NEOPLASMS;

EID: 84893607240     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083959     Document Type: Article

References (56)

1. Lee KJ, Inoue M, Otani T, Iwasaki M, Sasazuki S, et al. (2006) Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 118: 2315-2321.
2. Miyamoto A, Kuriyama S, Nishino Y, Tsubono Y, Nakaya N, et al. (2007) Lower risk of death from gastric cancer among participants of gastric cancer screening in Japan: a population-based cohort study. Prev Med 44: 12-19. (Pubitemid 46073076)
3. Hosokawa O, Miyanaga T, Kaizaki Y, Hattori M, Dohden K, et al. (2008) Decreased death from gastric cancer by endoscopic screening: association with a population-based cancer registry. Scand J Gastroenterol 43: 1112-1115.
4. Tsuji I, Tsubono Y, Hisamichi S (2001) Effectiveness and cost-benefit of screening for gastric cancer in Japan. Nihon Rinsho 59 Suppl 4: 533-537.
5. Lee YC, Lin JT, Wu HM, Liu TY, Yen MF, et al. (2007) Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev 16: 875-885.
6. Chang HS, Park EC, Chung W, Nam CM, Choi KS, et al. (2012) Comparing endoscopy and upper gastrointestinal X-ray for gastric cancer screening in South Korea: a cost-utility analysis. Asian Pac J Cancer Prev 13: 2721-2728.
7. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JW (2002) The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 50: 378-381. (Pubitemid 34161055)
8. Yeh JM, Hur C, Kuntz KM, Ezzati M, Goldie SJ (2010) Cost-effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer 116: 2941-2953.
9. Yeh JM, Ho W, Hur C (2010) Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointest Endosc 72: 33-43.
10. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Moreira-Dias L (2007) Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. J Gastroenterol Hepatol 22: 1594-1604. (Pubitemid 47383332)
11. Hassan C, Zullo A, Di Giulio E, Annibale B, Lahner E, et al. (2010) Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia. Helicobacter 15: 221-226.
12. Singapore Cancer Registry Committee (2012) Trends in cancer incidence in Singapore 1968-2007. singapore. 191 p.
13. Dan YY, So JB, Yeoh KG (2006) Endoscopic screening for gastric cancer. Clin Gastroenterol Hepatol 4: 709-716. (Pubitemid 43825816)
14. Xie F, Luo N, Blackhouse G, Goeree R, Lee HP (2008) Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in Chinese. Int J Technol Assess Health Care 24: 87-95. (Pubitemid 351158547)
15. Zhu F, Loh M, Hill J, Lee S, Koh KX, et al. (2009) Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: a cohort study. BMC Gastroenterol 9: 76.
16. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, et al. (2012) Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 44: 74-94.
17. Tsubono Y, Nishino Y, Tsuji I, Hisamichi S (2000) Screening for Gastric Cancer in Miyagi, Japan: Evaluation with a Population-Based Cancer Registry. Asian Pac J Cancer Prev 1: 57-60.
18. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, et al. (2004) Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291: 187-194. (Pubitemid 38082812)
19. Zhou HJ, So JB, Yong WP, Luo N, Zhu F, et al. (2012) Validation of the functional assessment of cancer therapy-gastric module for the Chinese population. Health Qual Life Outcomes 10: 145.
20. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA : the journal of the American Medical Association 276: 1253-1258.
21. Department of Statistics Singapore (2012) Yearbook of Statistics Singapore 2012. Singapore Ministry of Trade & Industry, Republic of Singapore. 319 p.
22. U.S. Environmental Protection Agency (2010) Cost of Illness Hand book 1st ed. Pennsylvania US Environmental Protection Agency.
23. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, et al. (2005) Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 54: 764-768. (Pubitemid 40732089)
24. Ang TL, Fock KM, Dhamodaran S, Teo EK, Tan J (2005) Racial differences in Helicobacter pylori, serum pepsinogen and gastric cancer incidence in an urban Asian population. J Gastroenterol Hepatol 20: 1603-1609. (Pubitemid 43961118)
25. Kim YS, Park HA, Kim BS, Yook JH, Lee MS (2000) Efficacy of screening for gastric cancer in a Korean adult population: a case-control study. J Korean Med Sci 15: 510-515.
26. Kubota H, Kotoh T, Masunaga R, Dhar DK, Shibakita M, et al. (2000) Impact of screening survey of gastric cancer on clinicopathological features and survival: retrospective study at a single institution. Surgery 128: 41-47. (Pubitemid 30456894)
27. Nakashima H, Nagahama R, Yamamoto T, Ohkura Y (2010) Mass screening for gastric cancer: how to select patients for endoscopic examination. Gastric Cancer 13: 78-83.
28. Voutilainen ME, Juhola MT (2005) Evaluation of the diagnostic accuracy of gastroscopy to detect gastric tumours: clinicopathological features and prognosis of patients with gastric cancer missed on endoscopy. Eur J Gastroenterol Hepatol 17: 1345-1349. (Pubitemid 41830456)
29. Environmental Protection Agency USA (2000) Cost of Stomach Cancer. Cost of Illness Handbook. washington DC: Environmental Protection Agency USA. pp. 1-45.
30. Morabito A, Carillio G, Longo R (2009) Systemic treatment of gastric cancer. Crit Rev Oncol Hematol 70: 216-234.
31. Zhou HJ, Li SC, Naidoo N, Zhu F, Yeoh KG (2013) Empirical evidence of the continuing improvement in cost efficiency of an endoscopic surveillance programme for gastric cancer in Singapore from 2004 to 2010. BMC Health Serv Res 13: 139.
32. Centers for Disease Control and Prevention NBCCEDP (2005) Policies and Procedures manual. Atlanta: Centers Disease Control & Prevention,
33. Subramanian S, Tangka FKL, Hoover S, DeGroff A, Royalty J, et al. (2011) Clinical and programmatic costs of implementing colorectal cancer screening: Evaluation of five programs. Evaluation and program planning 34: 147-153.
34. Commission on Macroeconomics and Health (2001) Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization.
35. Thompson SG, Barber JA (2000) How should cost data in pragmatic randomised trials be analysed? BMJ 320: 1197-1200. (Pubitemid 30224273)
36. Koong HN, Chan HS, Nambiar R, Soo KC, Ho J, et al. (1996) Gastric cancers in Singapore: poor prognosis arising from late presentation. Aust N Z J Surg 66: 813-815. (Pubitemid 27014057)
37. Wai CT, Yeoh KG, Ho KY, Kang JY, Lim SG (2002) Diagnostic yield of upper endoscopy in Asian patients presenting with dyspepsia. Gastrointest Endosc 56: 548-551.
38. Robert G, Brown J, Garvican L (2000) Cost of quality management and information provision for screening: colorectal cancer screening. Journal of medical screening 7: 31-34. (Pubitemid 30305464)
39. Weinstein MC, O'Brien B, Hornberger J, Jackson J, Johannesson M, et al. (2003) Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 6: 9-17. (Pubitemid 36228345)
40. Xie F, O'Reilly D, Ferrusi IL, Blackhouse G, Bowen JM, et al. (2009) Illustrating economic evaluation of diagnostic technologies: comparing Helicobacter pylori screening strategies in prevention of gastric cancer in Canada. J Am Coll Radiol 6: 317-323.
41. Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, et al. (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19: 422-437.
42. Fock KM, Talley N, Moayyedi P, Hunt R, Azuma T, et al. (2008) Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 23: 351-365. (Pubitemid 351342074)
43. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, et al. (2008) Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 9: 279-287. (Pubitemid 351722947)
44. Chien PF, Khan KS (2001) Evaluation of a clinical test. II: Assessment of validity. BJOG 108: 568-572.
45. Gupta N, Bansal A, Wani SB, Gaddam S, Rastogi A, et al. (2011) Endoscopy for upper GI cancer screening in the general population: a cost-utility analysis. Gastrointest Endosc 74: 610-624 e612.
46. Kang JM, Shin DW, Kwon YM, Park SM, Park MS, et al. (2011) Stomach cancer screening and preventive behaviors in relatives of gastric cancer patients. World J Gastroenterol 17: 3518-3525.
47. Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, et al. (2007) Serum pepsinogen and gastric cancer screening. Intern Med 46: 261-266. (Pubitemid 46488392)
48. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, et al. (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404: 398-402. (Pubitemid 30164342)
49. Walter LC, Lindquist K, Nugent S, Schult T, Lee SJ, et al. (2009) Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann Intern Med 150: 465-473.
50. Liu CY, Wu CY, Lin JT, Lee YC, Yen AM, et al. (2006) Multistate and multifactorial progression of gastric cancer: results from community-based mass screening for gastric cancer. J Med Screen 13 Suppl 1: S2-5.
51. Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, et al. (2004) Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 109: 138-143. (Pubitemid 38160674)
52. Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M (2013) Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-effectiveness studies. Helicobacter 18: 325-337.
53. Barton GR, Briggs AH, Fenwick EA (2008) Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the costeffectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health 11: 886-897.
54. Kwon YM, Lim HT, Lee K, Cho BL, Park MS, et al. (2009) Factors associated with use of gastric cancer screening services in Korea. World J Gastroenterol 15: 3653-3659.
55. Choi KS, Kwak MS, Lee HY, Jun JK, Hahm MI, et al. (2009) Screening for gastric cancer in Korea: population-based preferences for endoscopy versus upper gastrointestinal series. Cancer Epidemiol Biomarkers Prev 18: 1390-1398.
56. Shapiro J (1982) Evaluation as theory testing: An example from Head Start. Educational Evaluation and Policy Analysis,: 341-353.